zzlangerhans

Healthcare 'Debate' Dominated by Shouting and Lobbies

Any other docs here? As an emergency room physician, I support health care reform because I know the current system sucks. Insurance is too expensive and many people can't afford it or simply choose not to buy it and take their chances. This is the case because doctors waste enormous resources to practice defensive medicine and for unnecessary tests and hospitalizations to please overentitled patients. This problem can be addressed in two ways. One is to simply pump money into the system to support expansion of the current wasteful system, which appears to be the gist of the current proposals. This is probably better than doing nothing, but still not very good and unsustainable in the long term.

A much better approach would be to enact tort reform and subject physicians to greater scrutiny regarding wasteful spending, and also create some accountability from individuals regarding the health care spending on their behalf. It appears that the current powers do not have the motivation or willpower to adopt the second approach and therefore will never achieve credibility for their efforts among physicians.

Hemispherx Biopharma: Hot and Likely to Get Hotter

Your writing would benefit from a little more critical thinking and due diligence. If you rely entirely on corporate press releases for your research you're going to get your clock cleaned in this sector. Hemispheryx is a scam and a lot of people are going to get wiped when the Ampligen NDA gets rejected. How's that NFLD recommendation working out? You forgot to mention in that article that the Polyheme arm had a higher death rate than saline in the phase III trial. Everyone knew that was a dead NDA walking. Same for Ampligen snake oil ...

Six Reasons to Like the Morgan Stanley Emerging Market Domestic Debt Fund

Wow, EDD at 7.5. Goes to show what happens if you take advice from someone on a stock blog posting as the_pig_man.

Six Reasons to Like the Morgan Stanley Emerging Market Domestic Debt Fund

All the things you're saying were also true (and were being said) when EDD traded at 18, except the yield was a little lower. The EDD share price has dropped because NAV has dropped. The dividends haven't compensated for half the loss of someone buying at 18 a year ago. What people miss about EDD is that it does not represent a true diversification from the US market, as emerging markets are highly dependent on a healthy US economy and also benefit from a strong dollar in terms of trade. Long term holders of EDD are feeling a lot of pain and there's no reason to think it won't continue.

Oculus Innovative Sciences, Inc. F4Q08 (Qtr End 03/31/08) Earnings Call Transcript

Does anyone proofread these transcripts? "The India approval in the United States" ... could that be the NDA approval? And repeated a dozen times in the text. Pretty significant confusion gets generated by these errors.